Bicara Therapeutics price target raised to $16 from $14 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Bicara Therapeutics (BCAX) to $16 from $14 and keeps a Neutral rating on the shares. Bicara Therapeutics reported Q4 and full-year results, said it advanced the 1500mg QW dose into Phase 3 FORTIFI-HN01 in 1L R/M HNSCC, reaffirmed a mid-2027 interim analysis to support a BLA filing, continues discussions with the FDA on a less frequent dosing regimen ahead of ficera’s potential approval, and plans key commercial hires by YE26, with longer-term Phase 1b data to be presented at ASCO 2026, the analyst tells investors in a research note.